On April 5, 2021, Frank McCormick Ph.D., F.R.S., D.Sc. (Hon), a director of Olema Pharmaceuticals, Inc. notified the Company of his decision to resign as a member of the Company's Board of Directors, which resignation became effective immediately. On April 5, 2021, upon the recommendation of the Nominating and Corporate Governance Committee of the Board, the Board appointed Yi Larson to the Board as a Class III director to fill the vacancy left by Dr. McCormick's resignation, which appointment became effective immediately. Ms. Larson's term will expire, along with the terms of the other Class III directors, at the Company's annual meeting of stockholders in 2023. The Board also appointed Ms. Larson to serve as a member of the Nominating Committee.